A 2025 survey of 322 older Canadians using cannabis for mental health finds most feel it is helpful and safe—but 62% experienced adverse effects including dizziness and mental alertness impairment in the past year.
STEPS Therapy for PTSD and Cannabis Use After Sexual Assault
Researchers tested a novel 5-session integrated therapy combining trauma writing and cannabis coping skills in three women following recent sexual assault. All showed reduced PTSD and cannabis use—but with no control group, natural recovery remains the key alternative explanation.
THC:CBD Oral Extract vs Nabiximols: Pilot Pharmacokinetic Study
New pilot data from 12 healthy adults show that oral THC:CBD extract produces higher peak plasma cannabinoid concentrations than nabiximols spray, but equivalent total drug exposure—raising questions about which formulation is best suited for which therapeutic context.
Cannabis and Testosterone: Higher Androgens in Young Male Users
Swiss researchers measured 70 steroids in 94 young men and found cannabis users had significantly higher testosterone, DHT, and androstenedione—but not adrenal androgens. This association study raises important questions about cannabis and male hormonal health, while stopping well short of proving cause and effect.
Medical Cannabis and ER Visits in Chronic Pain: What the Evidence Shows
Researchers at a cannabis certification company analyzed their own patients and found lower ER and urgent care visits among medical cannabis users—but major methodological and conflict-of-interest concerns limit what this study can tell us.
Cannabis Hyperemesis Syndrome in Youth: 2025 Evidence Review
A 2025 narrative review in IJERPH synthesizes what is known about Cannabis Hyperemesis Syndrome in youth—its phases, diagnosis, treatment, and public health context—while revealing how thin the underlying evidence actually is.
Cannabis Withdrawal Psychosis in Older Adult: Case Report Analysis
A 67-year-old woman developed paranoid delusions four weeks after stopping long-term heavy cannabis use. The symptoms resolved with short-term antipsychotic treatment. Here is a rigorous look at what this single case report means—and what it does not.
Cannabis App User Profiles: Motives and Readiness to Change
Researchers analyzed data from 2,578 users of the Swiss Stop-Cannabis app and found three distinct user profiles—coping-driven, socially motivated, and enhancement-seeking—each with different levels of problematic use and readiness to change. The findings suggest potential for tailored digital interventions, though clinical recommendations remain untested.
Cannabis, Alcohol & Liver Enzymes: Ghana Psychiatric Study Analysis
A Ghanaian cross-sectional study finds elevated AST, GGT, and bilirubin in psychiatric patients who use cannabis and/or alcohol, especially dual users—but uncontrolled confounders limit causal interpretation.
Cannabis Healthcare Visits Nearly Doubled 2017-2022, FDA Study
A federal descriptive study using FDA Sentinel data found that cannabis-related healthcare encounters among commercially insured adults aged 18–64 rose 71% over five years, but showed no meaningful difference based on whether states had legalized cannabis — a finding that diverges from prior research in older populations.